Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amrubicin vs Docetaxel in NSCLC
NCT01207011Phase 3Completed
- Sponsor
- Sumitomo Pharma
- Start
- Oct 2010
- Primary completion
- Jun 2014
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of amrubicin in non-small cell lung cancer (NSCLC), sponsored by Sumitomo Pharma. Started Oct 2010; status: completed.
02
Drugs
amrubicin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01207011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01207011.